FMC regimen
|
WikiDoc Resources for FMC regimen |
|
Articles |
|---|
|
Most recent articles on FMC regimen Most cited articles on FMC regimen |
|
Media |
|
Powerpoint slides on FMC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FMC regimen at Clinical Trials.gov Clinical Trials on FMC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FMC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FMC regimen Discussion groups on FMC regimen Patient Handouts on FMC regimen Directions to Hospitals Treating FMC regimen Risk calculators and risk factors for FMC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FMC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: FCM regimen
Overview
FMC regimen refers to a regimen consisting of fludarabine, cyclophosphamide and mitoxantrone used in the treatment of resistant or relapsed chronic lymphocytic leukaemia. [1]
Regimen
FFludarabine
CCyclophosphamide
MMitoxantrone
Indications
References
- ↑ 1.0 1.1 Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N; et al. (2002). "Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia". Br J Haematol. 119 (4): 976–84. PMID 12472576.